GHSR and Prader-Willi syndrome: These results show the potential of developing drugs that selectively act on subsets of neurons that express GHSR1a:DRD2 heteromers for treating obsessive eating disorders such as in PWS and for psychiatric disorders associated with irregularities in dopamine signaling.